Inhibition of human astrocyte and microglia neurotoxicity by calcium channel blockers

被引:55
|
作者
Hashioka, Sadayuki [1 ]
Klegeris, Andis [2 ]
McGeer, Patrick L. [1 ]
机构
[1] Univ British Columbia, Dept Psychiat, Kinsmen Lab Neurol Res, Vancouver, BC V6T 2A1, Canada
[2] Univ British Columbia, IK Barber Sch Arts & Sci, Dept Biol, Kelowna, BC V1V 1V7, Canada
关键词
Nimodipine; Verapamil; Astrocytes; Microglia; Interferon-gamma; STAT3; Neurodegeneration; NUCLEUS BASALIS MAGNOCELLULARIS; VERAPAMIL TREATMENT; ALZHEIMERS-DISEASE; RAT; NIMODIPINE; EXPRESSION; NEURONS; CELLS; NEUROPROTECTION; PHYSOSTIGMINE;
D O I
10.1016/j.neuropharm.2012.05.033
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
We examined the effects of L-type calcium channel blockers (CCBs) on toxicity exerted by activated human astrocytes and microglia towards SH-SY5Y human neuronal cells. The CCBs nimodipine (NDP) and verapamil (VPM) both significantly suppressed toxic secretions from human astrocytes and astrocytoma U-373 MG cells that were induced by interferon (IFN)-gamma. NDP also inhibited neurotoxic secretions of human microglia and monocytic THP-1 cells that were induced by the combination of lipopolysaccharide and IFN-gamma. In human astrocytes, both NDP and VPM reduced IFN-gamma-induced phosphorylation of signal transducer and activator of transcription (STAT) 3. They also inhibited the astrocytic production of IFN-gamma-inducible T cell alpha chemoattractant (I-TAC). These results suggest that CCBs attenuate IFN-gamma-induced neurotoxicity of human astrocytes through inhibition of the STAT3 signaling pathway. L-type CCBs, especially NDP, might be a useful treatment option for a broad spectrum of neurodegenerative diseases, including Alzheimer disease, where the pathology is believed to be exacerbated by neurotoxic glial activation. (C) 2012 Elsevier Ltd. All rights reserved.
引用
收藏
页码:685 / 691
页数:7
相关论文
共 50 条
  • [31] Intoxication by calcium channel blockers
    Angulo, Martin
    Grille, Pedro
    Albornoz, Henry
    Ignacio Alvez, Jose
    Bagnulo, Homero
    REVISTA MEDICA DEL URUGUAY, 2012, 28 (03): : 225 - 231
  • [32] CALCIUM-CHANNEL BLOCKERS
    LESLIE, JB
    TARDIFF, BE
    BAILLIERES CLINICAL ANAESTHESIOLOGY, 1995, 9 (01): : 181 - 205
  • [33] Calcium channel blockers: An update
    Eisenberg, MJ
    Brox, A
    Bestawros, AN
    AMERICAN JOURNAL OF MEDICINE, 2004, 116 (01): : 35 - 43
  • [34] CALCIUM-CHANNEL BLOCKERS
    AHMED, T
    IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA, 1990, 10 (03) : 515 - 529
  • [35] Phenylalkylamines as calcium channel blockers
    Awasthi, Anamika
    Yadav, Arpita
    JOURNAL OF CHEMICAL SCIENCES, 2007, 119 (05) : 565 - 570
  • [36] Calcium channel blockers in pregnancy
    Tchobroutsky, C
    PRESSE MEDICALE, 1996, 25 (28): : 1297 - 1300
  • [37] Calcium channel blockers and cancer
    Cohen, HJ
    Pieper, CF
    Hanlon, JT
    Wall, WE
    Burchett, BM
    Havlik, RJ
    AMERICAN JOURNAL OF MEDICINE, 2000, 108 (03): : 210 - 215
  • [38] CALCIUM-CHANNEL BLOCKERS
    DEEDWANIA, PC
    WESTERN JOURNAL OF MEDICINE, 1982, 137 (01): : 24 - 31
  • [39] ALLHAT and calcium channel blockers
    Proschan, M
    Davis, B
    Cutler, J
    Ford, C
    Furberg, C
    Grimm, R
    Oparil, S
    AMERICAN JOURNAL OF HYPERTENSION, 1997, 10 (01) : 142 - 143
  • [40] Calcium channel blockers and dementia
    Nimmrich, V.
    Eckert, A.
    BRITISH JOURNAL OF PHARMACOLOGY, 2013, 169 (06) : 1203 - 1210